For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on January 19th, 2023 | 11:24 CET
Nel after the ITM Power shock: Better to bet on BioNTech and Alpina Holdings?
The year 2022 was not the year of growth stocks. Will this change in 2023? The positive start to the current year shows that the chances of this happening are quite good; however, not in the hydrogen sector. The renewed warning from ITM Power is weighing on the entire sector and stoking fears that Nel, Plug Power & Co. will not be able to work off their full order books in 2023 either. That is where a look at other sectors and stocks can pay off. Example: Alpina Holdings from Singapore. The Company is growing at double-digit rates, and its valuation is incredibly low. BioNTech wants to expand further. Goldman Sachs expects strong newsflow from the cancer pipeline in 2023.
Read
Commented by Fabian Lorenz on January 17th, 2023 | 16:28 CET
Commodity stocks poised for a comeback? Barrick Gold, American Lithium, Globex Mining, Standard Lithium
Inflation is weakening, and the interest rate cycle is nearing its end. This argues for a comeback of gold mining stocks. In any case, the gold price is already pointing in the right direction. Now heavyweights like Barrick Gold must follow. Explorer shares offer disproportionate opportunities. However, Globex Mining is an interesting alternative for those who shy away from individual risks. With more than 200 investments in the commodity sector, the Canadians are positioned similarly to a fund. Currently, the cash balance alone corresponds to half of the market capitalization. In addition, there is positive news from the projects. The lithium sector is also starting to recover. Companies like Standard Lithium and American Lithium are recovering from the sell-off at the end of the year. In addition, takeover fantasy attracts.
Read
Commented by Fabian Lorenz on January 12th, 2023 | 14:20 CET
Shares ready for takeoff: Nel, Plug Power, BASF, Almonty Industries
The New Year rally is on! The Nel share has gained around 20% since New Year's Eve. There was a tailwind from Federal Minister of Economics Robert Habeck, including a major order from Germany. Analysts see further upside potential. This also applies to BASF. A US analyst sees an opportunity for a good 30% price gain for the chemical giant. BASF should benefit from the current sharp decline in gas prices. The agricultural boom is also playing into the DAX company's hands. Almonty Industries wants to benefit even more from the boom in electric mobility in the future. To this end, the Group intends to become one of the leading tungsten producers. The mega-mine in South Korea is scheduled to go into operation in the current year, 2023. Financing by the German KfW has been secured, and analysts see a share price potential of over 100%.
Read
Commented by Fabian Lorenz on January 4th, 2023 | 07:17 CET
Takeover fever 2023? BioNTech, Barrick Gold, Standard Lithium, Manuka Resources
The pharmaceutical sector was already in takeover fever last year. BioNTech partner Pfizer, among others, made several acquisitions. The hunger for acquisitions is likely to continue in the current year as major pharmaceutical and biotech companies are looking to fill up their pipelines. The current year could also be exciting for gold stocks. In 2022, companies failed to keep pace with the positive gold price. Producers of raw materials for the energy transition could also get into takeover fever. Manuka Resources could benefit from the latest two trends. The Canadians have just carried out a capital measure to advance their projects. Corporations could also target specialists like Standard Lithium. Rumours that Tesla is looking at lithium projects have been doing the rounds for a long time. And what about Barrick Gold and BioNTech?
Read
Commented by Fabian Lorenz on December 28th, 2022 | 08:05 CET
Outperformer stocks in 2023? BioNTech, Steinhoff, Saturn Oil + Gas, K+S
Will energy stocks continue to be outperformers in 2023? In any case, in 2022, MSCI World Energy clearly outperformed MSCI World. In the case of individual stocks, Shell, for example, has gained over 45% in the current year. Jefferies recommends the stock as a buy with a target price of GPX 3100 (pence). Warren Buffett has also invested billions in the oil sector in 2022. Chevron and Occidental Petroleum are among Berkshire Hathaway's seven largest holdings. Energy, after all, is likely to be in demand in 2023. Those looking to bet on a laggard should look at Saturn Oil & Gas. The Canadian oil producer faces a milestone in 2023, and analysts see over 200% upside potential. BioNTech enters the new year with solid newsflow. And what is Steinhoff doing after the horror news?
Read
Commented by Fabian Lorenz on December 27th, 2022 | 06:07 CET
Excitement at BASF, Nel ASA, Meta Materials: Shares for 2023
After a difficult 2022, investors are looking ahead to the coming year. In 2023, it will be important to pick the right stocks again because there will be winners - despite the war in Ukraine, high inflation and rising interest rates. At the same time, the price rockets of the old year are rarely also those of the new year. As is well known, BASF shares have struggled in 2022. If energy prices continue to ease, the high dividend yield, among other things, will entice investors. Also, there is news in the electromobility megamarket. There is no question that hydrogen offers huge opportunities worldwide. But companies like Nel and Plug Power must finally wake up faster and reduce losses. At Nel ASA, a sell recommendation weighed on the share price at the end of the year. Hot stock Meta Materials has already multiplied sales in the first 3 quarters of 2022, and the chances are good that the positive trend will continue in 2023. Then the Meta Materials share should also take off.
Read
Commented by Fabian Lorenz on December 21st, 2022 | 08:48 CET
BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?
Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.
Read
Commented by Fabian Lorenz on December 19th, 2022 | 13:57 CET
BioNTech top, Morphosys flop and Defence Therapeutics takeover candidate?
Biotech shares are volatile. Investors were reminded of this again just last week. Moderna shares initially rose by almost 30%, only to fall back by around 10% towards the weekend. But overall, the mood in the biotech segment was positive. Moderna reported positive study results on a combination therapy of a Moderna cancer vaccine and the tumor drug pembrolizumab from Merck & Co. At BioNTech, two buy recommendations and the expansion in Asia created a good mood. This mood has also prevailed at Defence Therapeutics for several weeks. The Canadians reported positive study results against tumors, and their Accum technology delivers what it promises, in which case mRNA specialists such as Moderna, BioNTech and Co. should be interested in a cooperation or even acquisition. In contrast, Morphosys slides to a new multi-year low.
Read
Commented by Fabian Lorenz on December 15th, 2022 | 12:05 CET
E-car boom in Germany: BYD, Plug Power and dynaCERT are profiteers of the energy transition
The trend toward e-cars continues. In November 2022, 260,512 passenger cars were newly registered in Germany (source: kba.de). That represents an increase of 31% compared to the previous year. New registrations of electric passenger cars (BEV) increased disproportionately by 44% to 57,980 units. Significantly, Tesla's Model 3 was the most-registered car in the mid-size segment, while the Porsche Taycan was the most-registered car in the luxury segment - across all drive types. The trend toward electromobility should continue in the coming year. That is also when BYD plans to shake up the market in Europe. As a result, the excitement for shareholders is rising. The same applies to Plug Power and dynaCERT. Both are facing milestones in 2023 that should catapult share prices to new heights.
Read
Commented by Fabian Lorenz on December 14th, 2022 | 12:02 CET
Bayer, BioNTech, Auxico Resources: 200% price gain possible?
With lower than expected inflation in the US, the year-end rally has picked up speed. Could the recession be off after all, or at least short-lived? This would likely boost the stock market in the coming year as well. Today we look at three stocks with potential that benefit from global trends and less from developments in Germany. In the case of Bayer, Bernstein Research has outed itself as a super bull. The global agricultural business should continue to run strong. Auxico Resources is positioning itself as a trader of rare earths and critical raw materials. Revenues are expected to jump significantly in the coming year, and analysts say the stock could triple. BioNTech could finally break out of the sideways trend it has been in since early 2022. The new combination vaccine and the cancer pipeline give hope.
Read